Literature DB >> 19453761

Medicines submitted to narcotics regulations in France, 1992-2007.

Marie Baumevieille1, Amélie Daveluy, Catherine Maurain, Bernard Bégaud, Françoise Haramburu.   

Abstract

The objective was to study the current narcotics regulations which are the most restrictive regarding prescription and dispensation practice in France, and their evolution over the period 1992-2007. This is an example of regulation in a European member state regarding medicines with a risk of abuse or dependence. Narcotics regulations were studied in the French public health code. Status and indications of medicines concerned were found on the French medicine agency website, and the retrospective part of the study was conducted using the French public statute law website. Seventeen medicines were found. Three were psychotropics and fourteen narcotics. The prescription rules could be different for a given substance according to the route of administration or indication. In 2007, half of the narcotic opioids could be prescribed for 28 days, whereas in 1992, most of them could be prescribed for only 7 days. These results show the adaptation of French narcotics regulations, with the development of medicines indicated in acute or chronic pain treatment or opioid maintenance treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19453761     DOI: 10.1111/j.1472-8206.2009.00678.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  5 in total

1.  A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019).

Authors:  Joelle Perri-Plandé; Ghada Miremont-Salamé; Joëlle Micallef; Cameron Herman; Marie Baumevieille; Frédéric Abriat; Maryse Lapeyre-Mestre; Françoise Haramburu; Amélie Daveluy
Journal:  Drug Saf       Date:  2021-10-29       Impact factor: 5.606

2.  Novel forms of injectable buprenorphine and French model of opioid use disorder treatment.

Authors:  Maryse Lapeyre-Mestre
Journal:  Therapie       Date:  2020-09-28       Impact factor: 2.070

3.  Cannabis use: signal of increasing risk of serious cardiovascular disorders.

Authors:  Emilie Jouanjus; Maryse Lapeyre-Mestre; Joelle Micallef
Journal:  J Am Heart Assoc       Date:  2014-04-23       Impact factor: 5.501

Review 4.  Early Detection of Prescription Drug Abuse Using Doctor Shopping Monitoring From Claims Databases: Illustration From the Experience of the French Addictovigilance Network.

Authors:  Thomas Soeiro; Clémence Lacroix; Vincent Pradel; Maryse Lapeyre-Mestre; Joëlle Micallef
Journal:  Front Psychiatry       Date:  2021-05-17       Impact factor: 4.157

5.  Study protocol of the ESUB-MG cluster randomized trial: a pragmatic trial assessing the implementation of urine drug screening in general practice for buprenorphine maintained patients.

Authors: 
Journal:  BMC Fam Pract       Date:  2016-03-01       Impact factor: 2.497

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.